Clinical Observation Of Runzaozhiyang Capsule In The Treatment Of Chronic Urticaria Hemopenia Type

Objective:Clinical observation of Runzaozhiyang Capsule in the treatment of chronic urticaria hemopenia type. The purposes are to observe Runzao Zhiyang Capsule in the treatment of chronic urticaria and to assess its safety.Method:All patients were selected from July2012to March2013, Wuhan General Hospital of Guangzhou Command. Experimental design collection of80cases of Chronic Urticaria Hemopenia Type, through a random number table, were randomly divided into experimental group and control group. We actually completed70cases. Experimental group have33cases, including16males and17females, aged18-78years old, duration of18-252weeks. Control group have37cases, including18males and19females, with an average age of18-84years of age, duration of12-340weeks. The control group was given hydrochloric ebastine tablets10mg every day and intramusculared BCG-PSN2ml once every other day. The experimental group was plused Runzao Zhiyang Capsule on the basis of the control group,1g three times a day.We refered to European MILOR study and four score to evaluate before and after treatment of the signs and symptoms. Efficacy assessment based on symptom score reducing index (SSRI), Cure in the range of SSRI、90%, marked effect SSRI in the range of60%to89%, effective SSRI in the range of30%to59%, the invalid of SSRI<29%. We asked the patient to record the experimental group and the treatment group one week before treatment of the onset times, the treatment of fouth week of the onset times, the treatment of the eighth week of the onset times.We observed and recorded the adverse reactions of the two groups.We processed the data by using statistical software SPSS20.0. Measurement data were compared using T test.Count data were compared using the chi-square test.When the total number of cases was less than40or theoretical frequency was less than1, we used Fisher’s exact test method; All statistical tests were taken two-sided test, p<0.05was considered statistically significant.Results:Four weeks of treatment, the experimental group was better than the control group, the experimental group and the control group efficiency were69.70%and43.24%(X2=4.947,p=0.026); Eight weeks of treatment, the experimental group was better than the control group, the experimental group and the control group efficiency were93.94%and75.68%(X2=4.393,p=0.036)Four weeks of treatment, the average weekly number of episodes of the experimental group was4.36±1.25, the average weekly number of episodes of the control group was5.05±1.18, the number of weekly incidence of the experimental was lower than the control group (t=-2.383, p=0.020); Eight weeks of treatment, the average weekly number of episodes of the experimental group was2.12±1.65, the average weekly number of episodes of the control group was3.43±2.23. the number of incidence of the experimental group was lower than the control group (t=-2.315, p=0.024).Four weeks after the end of treatment, follow-up to cure patients, Experimental group had two cases of recurrence. The control group had six cases of recurrence. The recurrence rate of the experimental group and the control group were11.76%and60%(p=0.025)The experimental group by treatment had one case drowsiness. The control group by treatment had two cases drowsiness. The adverse reaction rate of he experimental group and the control group were3.57%and5.41%(X3=0.00, p=1.00)Conelusion:Runzao Zhiyang Capsule combined with hydrochloride ebastine tablet and BCG-PSN in the treatment of chronic urticaria Hemopenia Type could improve the effect, reduce the number of weekly incidence, reduce the relapse rate, and good security.